Clinical development of mRNA therapies against solid tumors

The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of this area is expanding from infectious disease to cancer, which needs to be summarized to provide data supports for industries and research institutions. Based on the Trialtrove dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Dawei, Hu, Lingfeng, Wang, Xin, Yu, Yue, Jia, Shuo-Peng, Huang, Hui-Yao, Li, Zi-Wei, Ma, Jin-Feng, Zhu, Hai-Bo, Tang, Yu, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354897/
https://www.ncbi.nlm.nih.gov/pubmed/37464375
http://dx.doi.org/10.1186/s13045-023-01457-x
_version_ 1785075020323618816
author Wu, Dawei
Hu, Lingfeng
Wang, Xin
Yu, Yue
Jia, Shuo-Peng
Huang, Hui-Yao
Li, Zi-Wei
Ma, Jin-Feng
Zhu, Hai-Bo
Tang, Yu
Li, Ning
author_facet Wu, Dawei
Hu, Lingfeng
Wang, Xin
Yu, Yue
Jia, Shuo-Peng
Huang, Hui-Yao
Li, Zi-Wei
Ma, Jin-Feng
Zhu, Hai-Bo
Tang, Yu
Li, Ning
author_sort Wu, Dawei
collection PubMed
description The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of this area is expanding from infectious disease to cancer, which needs to be summarized to provide data supports for industries and research institutions. Based on the Trialtrove database, a total of 108 clinical trials from 1999 to 2021 were retrospectively analyzed. We have demonstrated that the clinical development of mRNA therapies against solid tumors is still at an early stage. There are evolutions in delivery systems from the dendritic cell to the lipid-based platform and in encoding strategies from the fixed tumor antigens to the personalized neoantigens. The adjuvant or maintenance therapy and the combination treatment with checkpoint inhibitors are becoming the major clinical development orientation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-023-01457-x.
format Online
Article
Text
id pubmed-10354897
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103548972023-07-20 Clinical development of mRNA therapies against solid tumors Wu, Dawei Hu, Lingfeng Wang, Xin Yu, Yue Jia, Shuo-Peng Huang, Hui-Yao Li, Zi-Wei Ma, Jin-Feng Zhu, Hai-Bo Tang, Yu Li, Ning J Hematol Oncol Correspondence The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of this area is expanding from infectious disease to cancer, which needs to be summarized to provide data supports for industries and research institutions. Based on the Trialtrove database, a total of 108 clinical trials from 1999 to 2021 were retrospectively analyzed. We have demonstrated that the clinical development of mRNA therapies against solid tumors is still at an early stage. There are evolutions in delivery systems from the dendritic cell to the lipid-based platform and in encoding strategies from the fixed tumor antigens to the personalized neoantigens. The adjuvant or maintenance therapy and the combination treatment with checkpoint inhibitors are becoming the major clinical development orientation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-023-01457-x. BioMed Central 2023-07-18 /pmc/articles/PMC10354897/ /pubmed/37464375 http://dx.doi.org/10.1186/s13045-023-01457-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Wu, Dawei
Hu, Lingfeng
Wang, Xin
Yu, Yue
Jia, Shuo-Peng
Huang, Hui-Yao
Li, Zi-Wei
Ma, Jin-Feng
Zhu, Hai-Bo
Tang, Yu
Li, Ning
Clinical development of mRNA therapies against solid tumors
title Clinical development of mRNA therapies against solid tumors
title_full Clinical development of mRNA therapies against solid tumors
title_fullStr Clinical development of mRNA therapies against solid tumors
title_full_unstemmed Clinical development of mRNA therapies against solid tumors
title_short Clinical development of mRNA therapies against solid tumors
title_sort clinical development of mrna therapies against solid tumors
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354897/
https://www.ncbi.nlm.nih.gov/pubmed/37464375
http://dx.doi.org/10.1186/s13045-023-01457-x
work_keys_str_mv AT wudawei clinicaldevelopmentofmrnatherapiesagainstsolidtumors
AT hulingfeng clinicaldevelopmentofmrnatherapiesagainstsolidtumors
AT wangxin clinicaldevelopmentofmrnatherapiesagainstsolidtumors
AT yuyue clinicaldevelopmentofmrnatherapiesagainstsolidtumors
AT jiashuopeng clinicaldevelopmentofmrnatherapiesagainstsolidtumors
AT huanghuiyao clinicaldevelopmentofmrnatherapiesagainstsolidtumors
AT liziwei clinicaldevelopmentofmrnatherapiesagainstsolidtumors
AT majinfeng clinicaldevelopmentofmrnatherapiesagainstsolidtumors
AT zhuhaibo clinicaldevelopmentofmrnatherapiesagainstsolidtumors
AT tangyu clinicaldevelopmentofmrnatherapiesagainstsolidtumors
AT lining clinicaldevelopmentofmrnatherapiesagainstsolidtumors

Ejemplares similares